A pragmatic controlled clinical trial investigating the efficacy of low-level laser therapy as a part of the palliative management of the hand symptoms of rheumatoid arthritis [thesis]

Keriann Stagg
The purpose of this pragmatic controlled clinical trial was to investigate the efficacy of low-level laser therapy (LLL T) as a part of the palliative management of the hand symptoms of rheumatoid arthritis (RA). The results were based upon subjective and objective clinical findings. LLLT may offer a viable treatment option for the hand symptoms of RA as its application theoretically supports and suggests that the physiological effects of LLL Tare biostimulation, improved metabolism, increased
more » ... ell metabolism, improved blood circulation, vasodilatation, analgesic effects, anti-inflammatory and anti-edematous effects; all of which are desired in the treatment of RA (Baxter, 1994; Kahn, 1994, Liggins, 2002). There is however controversy within the literature as to the efficacy of LLLT (Asada et al., 1991; Bliddal et al., 1987; Goats. et al., 1996; Hall et al., 1994; Heussier et al., 1993; Johannsen et al., 1994; Palmagren et al., 1989; Walker et aI., 1987). This is partially attributable to the lack of consensus regarding the methodology applied in these studies. Other inconsistencies regarding the efficacy of laser in the treatment of RA exist due to the wide range of differing wavelengths and doses that have been used in the published reports, thereby making it difficult to effectively compare studies (Asada et al., 1991; Goats et al., 1996; Hall et ai., 1994; Haslett et al., 2001, Heussier et ai., 1993; Johannsen et al., 1994; Palmagren et al., 1989; Walker et al., 1987). This study included a sample of 24 patients with rheumatoid arthritis. They were divided into two groups (Group A and Group B) based on their DASH score and their primary medication. Group A (treatment group) received LLLT of the metacarpophalangeal (Mep) joints and proximal interphalangeal (PIP) joints of their more severely affected hand. Patients in Group B (placebo
doi:10.51415/10321/2109 fatcat:apq26pbi2ve2rbhmrmzibuqswm